ID   HIPK2_HUMAN             Reviewed;        1198 AA.
AC   Q9H2X6; Q75MR7; Q8WWI4; Q9H2Y1;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   06-JUN-2002, sequence version 2.
DT   12-OCT-2022, entry version 211.
DE   RecName: Full=Homeodomain-interacting protein kinase 2;
DE            Short=hHIPk2;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:33591310};
GN   Name=HIPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF LYS-228.
RC   TISSUE=Liver, and Testis;
RX   PubMed=11267674; DOI=10.1016/s0167-4781(00)00308-0;
RA   Wang Y., Hofmann T.G., Runkel L., Haaf T., Schaller H., Debatin K.-M.,
RA   Hug H.;
RT   "Isolation and characterization of cDNAs for the protein kinase HIPK2.";
RL   Biochim. Biophys. Acta 1518:168-172(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Frontal cortex;
RA   Stukart G.C., Dias-Neto E.;
RT   "Sequencing of hHIPk2, a human homolog of mouse homeodomain interacting
RT   protein kinase 2.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 8-1198 (ISOFORM 2).
RA   Pierantoni G.M., Benvenuto G., Chiariotti L., Fusco A.;
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH TRADD.
RX   PubMed=11032752; DOI=10.1006/bbrc.2000.3700;
RA   Li X., Wang Y., Debatin K.-M., Hug H.;
RT   "The serine/threonine kinase HIPK2 interacts with TRADD, but not with CD95
RT   or TNF-R1 in 293T cells.";
RL   Biochem. Biophys. Res. Commun. 277:513-517(2000).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=11798164; DOI=10.1006/bbrc.2001.6310;
RA   Pierantoni G.M., Bulfone A., Pentimalli F., Fedele M., Iuliano R.,
RA   Santoro M., Chiariotti L., Ballabio A., Fusco A.;
RT   "The homeodomain-interacting protein kinase 2 gene is expressed late in
RT   embryogenesis and preferentially in retina, muscle, and neural tissues.";
RL   Biochem. Biophys. Res. Commun. 290:942-947(2002).
RN   [7]
RP   INTERACTION WITH RANBP9, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-228.
RX   PubMed=12220523; DOI=10.1016/s0006-291x(02)02020-x;
RA   Wang Y., Marion Schneider E., Li X., Duttenhoefer I., Debatin K.-M.,
RA   Hug H.;
RT   "HIPK2 associates with RanBPM.";
RL   Biochem. Biophys. Res. Commun. 297:148-153(2002).
RN   [8]
RP   INTERACTION WITH TP73; TP53 AND TP63, MUTAGENESIS OF LYS-228, AND FUNCTION.
RX   PubMed=11925430; DOI=10.1074/jbc.m200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [9]
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, INTERACTION WITH TP53 AND
RP   CREBBP, MUTAGENESIS OF LYS-228, FUNCTION, AND INDUCTION.
RX   PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-interacting
RT   protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [10]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-228.
RX   PubMed=12907596;
RA   Moeller A., Sirma H., Hofmann T.G., Rueffer S., Klimczak E., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-
RT   mediated p53 phosphorylation and cell cycle arrest but is dispensable for
RT   the formation of HIPK domains.";
RL   Cancer Res. 63:4310-4314(2003).
RN   [11]
RP   FUNCTION, INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-228.
RX   PubMed=14678985;
RA   Hofmann T.G., Stollberg N., Schmitz M.L., Will H.;
RT   "HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-
RT   terminal kinase activation and apoptosis in human hepatoma cells.";
RL   Cancer Res. 63:8271-8277(2003).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH P53DINP1.
RX   PubMed=12851404; DOI=10.1074/jbc.m301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S.,
RA   Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [13]
RP   FUNCTION, INTERACTION WITH SKI; SMAD1; SMAD2 AND SMAD3, AND MUTAGENESIS OF
RP   LYS-228 AND 359-SER--TYR-361.
RX   PubMed=12874272; DOI=10.1074/jbc.m307112200;
RA   Harada J., Kokura K., Kanei-Ishii C., Nomura T., Khan M.M., Kim Y.,
RA   Ishii S.;
RT   "Requirement of the co-repressor homeodomain-interacting protein kinase 2
RT   for ski-mediated inhibition of bone morphogenetic protein-induced
RT   transcriptional activation.";
RL   J. Biol. Chem. 278:38998-39005(2003).
RN   [14]
RP   INTERACTION WITH HANTAAN HANTAVIRUS NUCLEOPROTEIN (MICROBIAL INFECTION),
RP   AND INTERACTION WITH SEOUL HANTAVIRUS NUCLEOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=14609633; DOI=10.1016/j.virusres.2003.09.001;
RA   Lee B.H., Yoshimatsu K., Maeda A., Ochiai K., Morimatsu M., Araki K.,
RA   Ogino M., Morikawa S., Arikawa J.;
RT   "Association of the nucleocapsid protein of the Seoul and Hantaan
RT   hantaviruses with small ubiquitin-like modifier-1-related molecules.";
RL   Virus Res. 98:83-91(2003).
RN   [15]
RP   INTERACTION WITH SP100.
RX   PubMed=14647468; DOI=10.1038/sj.onc.1207079;
RA   Moeller A., Sirma H., Hofmann T.G., Staege H., Gresko E., Luedi K.S.,
RA   Klimczak E., Droege W., Will H., Schmitz M.L.;
RT   "Sp100 is important for the stimulatory effect of homeodomain-interacting
RT   protein kinase-2 on p53-dependent gene expression.";
RL   Oncogene 22:8731-8737(2003).
RN   [16]
RP   DESUMOYLATION.
RX   PubMed=16253240; DOI=10.1016/j.febslet.2005.10.010;
RA   Kim Y.H., Sung K.S., Lee S.-J., Kim Y.-O., Choi C.Y., Kim Y.;
RT   "Desumoylation of homeodomain-interacting protein kinase 2 (HIPK2) through
RT   the cytoplasmic-nuclear shuttling of the SUMO-specific protease SENP1.";
RL   FEBS Lett. 579:6272-6278(2005).
RN   [17]
RP   CLEAVAGE BY CASP6 AT ASP-923 AND ASP-984.
RX   PubMed=16601678; DOI=10.1038/sj.emboj.7601077;
RA   Gresko E., Roscic A., Ritterhoff S., Vichalkovski A., del Sal G.,
RA   Schmitz M.L.;
RT   "Autoregulatory control of the p53 response by caspase-mediated processing
RT   of HIPK2.";
RL   EMBO J. 25:1883-1894(2006).
RN   [18]
RP   INTERACTION WITH CBX4, SUMOYLATION AT LYS-32, AND FUNCTION.
RX   PubMed=17018294; DOI=10.1016/j.molcel.2006.08.004;
RA   Roscic A., Moeller A., Calzado M.A., Renner F., Wimmer V.C., Gresko E.,
RA   Luedi K.S., Schmitz M.L.;
RT   "Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its
RT   substrate protein HIPK2.";
RL   Mol. Cell 24:77-89(2006).
RN   [19]
RP   FUNCTION AS HMGA1 KINASE.
RX   PubMed=17960875; DOI=10.1021/pr700571d;
RA   Zhang Q., Wang Y.;
RT   "Homeodomain-interacting protein kinase-2 (HIPK2) phosphorylates HMGA1a at
RT   Ser-35, Thr-52, and Thr-77 and modulates its DNA binding affinity.";
RL   J. Proteome Res. 6:4711-4719(2007).
RN   [20]
RP   FUNCTION AS RUNX1 AND EP300 KINASE, AND MUTAGENESIS OF LYS-228.
RX   PubMed=18695000; DOI=10.1182/blood-2008-01-134122;
RA   Wee H.-J., Voon D.C.-C., Bae S.-C., Ito Y.;
RT   "PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2:
RT   implications for leukemogenesis.";
RL   Blood 112:3777-3787(2008).
RN   [21]
RP   INTERACTION WITH WSB1, AND UBIQUITINATION BY WSB1.
RX   PubMed=18093972; DOI=10.1074/jbc.m708873200;
RA   Choi D.W., Seo Y.-M., Kim E.-A., Sung K.S., Ahn J.W., Park S.-J.,
RA   Lee S.-R., Choi C.Y.;
RT   "Ubiquitination and degradation of homeodomain-interacting protein kinase 2
RT   by WD40 repeat/SOCS box protein WSB-1.";
RL   J. Biol. Chem. 283:4682-4689(2008).
RN   [22]
RP   FUNCTION, AND UBIQUITINATION BY FBXO3.
RX   PubMed=18809579; DOI=10.1128/mcb.00897-08;
RA   Shima Y., Shima T., Chiba T., Irimura T., Pandolfi P.P., Kitabayashi I.;
RT   "PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-
RT   mediated degradation.";
RL   Mol. Cell. Biol. 28:7126-7138(2008).
RN   [23]
RP   INDUCTION BY DNA DAMAGE, INTERACTION WITH SIAH1, AND UBIQUITINATION BY
RP   SIAH1.
RX   PubMed=18536714; DOI=10.1038/ncb1743;
RA   Winter M., Sombroek D., Dauth I., Moehlenbrink J., Scheuermann K.,
RA   Crone J., Hofmann T.G.;
RT   "Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint
RT   kinases ATM and ATR.";
RL   Nat. Cell Biol. 10:812-824(2008).
RN   [24]
RP   FUNCTION AS HIF1A TRANSCRIPTION REGULATOR AND ANGIOGENESIS PROMOTER.
RX   PubMed=19046997; DOI=10.1016/j.bbamcr.2008.10.013;
RA   Nardinocchi L., Puca R., Guidolin D., Belloni A.S., Bossi G., Michiels C.,
RA   Sacchi A., Onisto M., D'Orazi G.;
RT   "Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2
RT   suggests a novel mechanism to restrain tumor growth.";
RL   Biochim. Biophys. Acta 1793:368-377(2009).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   FUNCTION AS PML KINASE, INTERACTION WITH PML, AND MUTAGENESIS OF LYS-228.
RX   PubMed=19015637; DOI=10.1038/onc.2008.420;
RA   Gresko E., Ritterhoff S., Sevilla-Perez J., Roscic A., Froebius K.,
RA   Kotevic I., Vichalkovski A., Hess D., Hemmings B.A., Schmitz M.L.;
RT   "PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in
RT   response to DNA damage.";
RL   Oncogene 28:698-708(2009).
RN   [27]
RP   FUNCTION AS ZBTB4 KINASE, AND INTERACTION WITH ZBTB4.
RX   PubMed=19448668; DOI=10.1038/onc.2009.109;
RA   Yamada D., Perez-Torrado R., Filion G., Caly M., Jammart B., Devignot V.,
RA   Sasai N., Ravassard P., Mallet J., Sastre-Garau X., Schmitz M.L.,
RA   Defossez P.A.;
RT   "The human protein kinase HIPK2 phosphorylates and downregulates the
RT   methyl-binding transcription factor ZBTB4.";
RL   Oncogene 28:2535-2544(2009).
RN   [28]
RP   INDUCTION BY ZINC DURING HYPOXIA.
RX   PubMed=19714248; DOI=10.1371/journal.pone.0006819;
RA   Nardinocchi L., Puca R., Sacchi A., Rechavi G., Givol D., D'Orazi G.;
RT   "Targeting hypoxia in cancer cells by restoring homeodomain interacting
RT   protein-kinase 2 and p53 activity and suppressing HIF-1alpha.";
RL   PLoS ONE 4:E6819-E6819(2009).
RN   [29]
RP   FUNCTION AS PDX1 KINASE.
RX   PubMed=20637728; DOI=10.1016/j.bbrc.2010.07.035;
RA   An R., da Silva Xavier G., Semplici F., Vakhshouri S., Hao H.X., Rutter J.,
RA   Pagano M.A., Meggio F., Pinna L.A., Rutter G.A.;
RT   "Pancreatic and duodenal homeobox 1 (PDX1) phosphorylation at serine-269 is
RT   HIPK2-dependent and affects PDX1 subnuclear localization.";
RL   Biochem. Biophys. Res. Commun. 399:155-161(2010).
RN   [30]
RP   FUNCTION AS CTNNB1 KINASE.
RX   PubMed=20307497; DOI=10.1016/j.bbrc.2010.03.099;
RA   Kim E.-A., Kim J.E., Sung K.S., Choi D.W., Lee B.J., Choi C.Y.;
RT   "Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for
RT   phosphorylation and proteasomal degradation.";
RL   Biochem. Biophys. Res. Commun. 394:966-971(2010).
RN   [31]
RP   FUNCTION AS ATF1 KINASE, AND INTERACTION WITH ATF1.
RX   PubMed=20980392; DOI=10.1242/jcs.073627;
RA   Hailemariam K., Iwasaki K., Huang B.W., Sakamoto K., Tsuji Y.;
RT   "Transcriptional regulation of ferritin and antioxidant genes by HIPK2
RT   under genotoxic stress.";
RL   J. Cell Sci. 123:3863-3871(2010).
RN   [32]
RP   FUNCTION AS CREB1 KINASE, AND INTERACTION WITH CREB1.
RX   PubMed=20573984; DOI=10.1091/mbc.e10-01-0015;
RA   Sakamoto K., Huang B.-W., Iwasaki K., Hailemariam K., Ninomiya-Tsuji J.,
RA   Tsuji Y.;
RT   "Regulation of genotoxic stress response by homeodomain-interacting protein
RT   kinase 2 through phosphorylation of cyclic AMP response element-binding
RT   protein at serine 271.";
RL   Mol. Biol. Cell 21:2966-2974(2010).
RN   [33]
RP   SUBCELLULAR LOCATION, SUMOYLATION, NUCLEAR LOCALIZATION SIGNALS,
RP   MUTAGENESIS OF LYS-803; LYS-805; ARG-833; LYS-835; 885-VAL--SER-892 AND
RP   893-ASP--GLU-899, AND INTERACTION WITH CBX4.
RX   PubMed=21145359; DOI=10.1016/j.bbamcr.2010.11.022;
RA   de la Vega L., Froebius K., Moreno R., Calzado M.A., Geng H., Schmitz M.L.;
RT   "Control of nuclear HIPK2 localization and function by a SUMO interaction
RT   motif.";
RL   Biochim. Biophys. Acta 1813:283-297(2011).
RN   [34]
RP   SUBCELLULAR LOCATION, SUMOYLATION, FUNCTION, AND MUTAGENESIS OF
RP   885-VAL--ILE-888 AND 892-SER--ASP-895.
RX   PubMed=21192925; DOI=10.1016/j.yexcr.2010.12.016;
RA   Sung K.S., Lee Y.A., Kim E.T., Lee S.R., Ahn J.H., Choi C.Y.;
RT   "Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear
RT   bodies and regulation of p53.";
RL   Exp. Cell Res. 317:1060-1070(2011).
RN   [35]
RP   REVIEW ON DNA DAMAGE SIGNALING, INDUCTION BY GENOTOXIC AGENTS, AND
RP   STABILIZATION BY DNA DAMAGE.
RX   PubMed=18974774; DOI=10.1038/cdd.2008.154;
RA   Sombroek D., Hofmann T.G.;
RT   "How cells switch HIPK2 on and off.";
RL   Cell Death Differ. 16:187-194(2009).
RN   [36]
RP   REVIEW.
RX   PubMed=19788416; DOI=10.1111/j.1742-4658.2009.07331.x;
RA   Bitomsky N., Hofmann T.G.;
RT   "Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling
RT   - roles of p53, p73 and HIPK2.";
RL   FEBS J. 276:6074-6083(2009).
RN   [37]
RP   REVIEW AS HYPOXIA AND TP53 REGULATOR.
RX   PubMed=20234185; DOI=10.4161/cc.9.7.11125;
RA   Nardinocchi L., Puca R., Givol D., D'Orazi G.;
RT   "HIPK2-a therapeutical target to be (re)activated for tumor suppression:
RT   role in p53 activation and HIF-1? inhibition.";
RL   Cell Cycle 9:1270-1275(2010).
RN   [38]
RP   REVIEW AS TP53 REGULATOR, AND INDUCTION BY GENOTOXIC AGENTS AND HYPOXIA.
RX   PubMed=20514025; DOI=10.1038/onc.2010.183;
RA   Puca R., Nardinocchi L., Givol D., D'Orazi G.;
RT   "Regulation of p53 activity by HIPK2: molecular mechanisms and
RT   therapeutical implications in human cancer cells.";
RL   Oncogene 29:4378-4387(2010).
RN   [39]
RP   FUNCTION.
RX   PubMed=22825850; DOI=10.1074/jbc.m112.390120;
RA   Pelisch F., Pozzi B., Risso G., Munoz M.J., Srebrow A.;
RT   "DNA damage-induced heterogeneous nuclear ribonucleoprotein K SUMOylation
RT   regulates p53 transcriptional activation.";
RL   J. Biol. Chem. 287:30789-30799(2012).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [41]
RP   INTERACTION WITH SUMO1P1/SUMO5, AND SUBCELLULAR LOCATION.
RX   PubMed=27211601; DOI=10.1038/srep26509;
RA   Liang Y.C., Lee C.C., Yao Y.L., Lai C.C., Schmitz M.L., Yang W.M.;
RT   "SUMO5, a novel poly-sumo isoform, regulates pml nuclear bodies.";
RL   Sci. Rep. 6:26509-26509(2016).
RN   [42]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32; LYS-953 AND LYS-973, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [43]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH DAZAP2 AND SIAH1,
RP   SUBCELLULAR LOCATION, UBIQUITINATION BY SIAH1, AND MUTAGENESIS OF LYS-228.
RX   PubMed=33591310; DOI=10.1093/nar/gkab084;
RA   Liebl M.C., Moehlenbrink J., Becker H., Raddatz G., Abdeen S.K.,
RA   Aqeilan R.I., Lyko F., Hofmann T.G.;
RT   "DAZAP2 acts as specifier of the p53 response to DNA damage.";
RL   Nucleic Acids Res. 49:2759-2776(2021).
RN   [44]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-792 AND GLN-1027.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in transcription
CC       regulation, p53/TP53-mediated cellular apoptosis and regulation of the
CC       cell cycle. Acts as a corepressor of several transcription factors,
CC       including SMAD1 and POU4F1/Brn3a and probably NK homeodomain
CC       transcription factors. Phosphorylates PDX1, ATF1, PML, p53/TP53, CREB1,
CC       CTBP1, CBX4, RUNX1, EP300, CTNNB1, HMGA1, ZBTB4 and DAZAP2. Inhibits
CC       cell growth and promotes apoptosis through the activation of p53/TP53
CC       both at the transcription level and at the protein level (by
CC       phosphorylation and indirect acetylation). The phosphorylation of
CC       p53/TP53 may be mediated by a p53/TP53-HIPK2-AXIN1 complex. Involved in
CC       the response to hypoxia by acting as a transcriptional co-suppressor of
CC       HIF1A. Mediates transcriptional activation of TP73. In response to
CC       TGFB, cooperates with DAXX to activate JNK. Negative regulator through
CC       phosphorylation and subsequent proteasomal degradation of CTNNB1 and
CC       the antiapoptotic factor CTBP1. In the Wnt/beta-catenin signaling
CC       pathway acts as an intermediate kinase between MAP3K7/TAK1 and NLK to
CC       promote the proteasomal degradation of MYB. Phosphorylates CBX4 upon
CC       DNA damage and promotes its E3 SUMO-protein ligase activity. Activates
CC       CREB1 and ATF1 transcription factors by phosphorylation in response to
CC       genotoxic stress. In response to DNA damage, stabilizes PML by
CC       phosphorylation. PML, HIPK2 and FBXO3 may act synergically to activate
CC       p53/TP53-dependent transactivation. Promotes angiogenesis, and is
CC       involved in erythroid differentiation, especially during fetal liver
CC       erythropoiesis. Phosphorylation of RUNX1 and EP300 stimulates EP300
CC       transcription regulation activity. Triggers ZBTB4 protein degradation
CC       in response to DNA damage. In response to DNA damage, phosphorylates
CC       DAZAP2 which localizes DAZAP2 to the nucleus, reduces interaction of
CC       DAZAP2 with HIPK2 and prevents DAZAP2-dependent ubiquitination of HIPK2
CC       by E3 ubiquitin-protein ligase SIAH1 and subsequent proteasomal
CC       degradation (PubMed:33591310). Modulates HMGA1 DNA-binding affinity. In
CC       response to high glucose, triggers phosphorylation-mediated subnuclear
CC       localization shifting of PDX1. Involved in the regulation of eye size,
CC       lens formation and retinal lamination during late embryogenesis.
CC       {ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11925430,
CC       ECO:0000269|PubMed:12851404, ECO:0000269|PubMed:12874272,
CC       ECO:0000269|PubMed:14678985, ECO:0000269|PubMed:17018294,
CC       ECO:0000269|PubMed:17960875, ECO:0000269|PubMed:18695000,
CC       ECO:0000269|PubMed:18809579, ECO:0000269|PubMed:19015637,
CC       ECO:0000269|PubMed:19046997, ECO:0000269|PubMed:19448668,
CC       ECO:0000269|PubMed:20307497, ECO:0000269|PubMed:20573984,
CC       ECO:0000269|PubMed:20637728, ECO:0000269|PubMed:20980392,
CC       ECO:0000269|PubMed:21192925, ECO:0000269|PubMed:22825850,
CC       ECO:0000269|PubMed:33591310}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:33591310};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:33591310};
CC   -!- SUBUNIT: Interacts with CREB1, SIAH1, WSB1, CBX4, TRADD, p53/TP53,
CC       TP73, TP63, CREBBP, DAXX, P53DINP1, SKI, SMAD1, SMAD2 and SMAD3, but
CC       not SMAD4. Interacts with ATF1, PML, RUNX1, EP300, NKX1-2, NKX2-5,
CC       UBE2I, HMGA1, CTBP1, AXIN1, NLK, MYB, POU4F1, POU4F2, POU4F3, UBE2I,
CC       UBL1 and ZBTB4. Probably part of a complex consisting of p53/TP53,
CC       HIPK2 and AXIN1. Interacts with SP100; positively regulates TP53-
CC       dependent transcription. Interacts with SUMO1P1/SUMO5
CC       (PubMed:27211601). Interacts with DAZAP2; the interaction results in
CC       phosphorylation of DAZAP2 which causes localization of DAZAP2 to the
CC       nucleus, reduces interaction of DAZAP2 with HIPK2 and prevents DAZAP2-
CC       dependent degradation of HIPK2 (PubMed:33591310). Interacts with SIAH1;
CC       the interaction is promoted by DAZAP2 and results in SIAH1-mediated
CC       ubiquitination and subsequent proteasomal degradation of HIPK2
CC       (PubMed:33591310). {ECO:0000269|PubMed:11032752,
CC       ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11925430,
CC       ECO:0000269|PubMed:12220523, ECO:0000269|PubMed:12851404,
CC       ECO:0000269|PubMed:12874272, ECO:0000269|PubMed:14647468,
CC       ECO:0000269|PubMed:14678985, ECO:0000269|PubMed:17018294,
CC       ECO:0000269|PubMed:18093972, ECO:0000269|PubMed:18536714,
CC       ECO:0000269|PubMed:19015637, ECO:0000269|PubMed:19448668,
CC       ECO:0000269|PubMed:20573984, ECO:0000269|PubMed:20980392,
CC       ECO:0000269|PubMed:21145359, ECO:0000269|PubMed:27211601,
CC       ECO:0000269|PubMed:33591310}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Hantaan hantavirus
CC       nucleoprotein. {ECO:0000269|PubMed:14609633}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Seoul hantavirus
CC       nucleoprotein. {ECO:0000269|PubMed:14609633}.
CC   -!- INTERACTION:
CC       Q9H2X6; P61962: DCAF7; NbExp=10; IntAct=EBI-348345, EBI-359808;
CC       Q9H2X6; Q09472: EP300; NbExp=4; IntAct=EBI-348345, EBI-447295;
CC       Q9H2X6; P51608: MECP2; NbExp=2; IntAct=EBI-348345, EBI-1189067;
CC       Q9H2X6; Q01196: RUNX1; NbExp=4; IntAct=EBI-348345, EBI-925904;
CC       Q9H2X6; Q9H3D4: TP63; NbExp=2; IntAct=EBI-348345, EBI-2337775;
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body {ECO:0000269|PubMed:27211601,
CC       ECO:0000269|PubMed:33591310}. Cytoplasm {ECO:0000269|PubMed:33591310}.
CC       Cytoplasm, Stress granule {ECO:0000269|PubMed:33591310}.
CC       Note=Concentrated in PML/POD/ND10 nuclear bodies. Small amounts are
CC       cytoplasmic.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Experimental confirmation may be lacking for some isoforms.;
CC       Name=1;
CC         IsoId=Q9H2X6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H2X6-2; Sequence=VSP_004805, VSP_004806, VSP_004807;
CC       Name=3;
CC         IsoId=Q9H2X6-3; Sequence=VSP_004804;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, muscle and kidney.
CC       Weakly expressed in a ubiquitous way. Down-regulated in several thyroid
CC       and breast tumors. {ECO:0000269|PubMed:11267674,
CC       ECO:0000269|PubMed:11798164}.
CC   -!- INDUCTION: Unstable in unstressed cells but stabilized upon DNA damage.
CC       Induced by UV irradiation and other genotoxic agents (adriamycin ADR,
CC       cisplatin CDDP, etoposide, IR, roscovitin), thus triggering p53/TP53
CC       apoptotic response. Consistutively negatively regulated by SIAH1 and
CC       WSB1 through proteasomal degradation. This negative regulation is
CC       impaired upon genotoxic stress. Repressed upon hypoxia (often
CC       associated with tumors), through MDM2- (an E3 ubiquitin ligases)
CC       mediated proteasomal degradation, thus inactivating p53/TP53 apoptotic
CC       response. This hypoxia repression is reversed by zinc. The
CC       stabilization mediated by DNA damage requires the damage checkpoint
CC       kinases ATM and ATR. {ECO:0000269|PubMed:11740489,
CC       ECO:0000269|PubMed:18536714, ECO:0000269|PubMed:18974774,
CC       ECO:0000269|PubMed:19714248, ECO:0000269|PubMed:20514025}.
CC   -!- PTM: Autophosphorylation at Tyr-361 in the activation loop activates
CC       the kinase and promotes nuclear localization. {ECO:0000250}.
CC   -!- PTM: Sumoylated. When conjugated it is directed to nuclear speckles.
CC       Desumoylated by SENP1 (By similarity). Sumoylation on Lys-32 is
CC       promoted by the E3 SUMO-protein ligase CBX4. {ECO:0000250,
CC       ECO:0000269|PubMed:16253240, ECO:0000269|PubMed:17018294,
CC       ECO:0000269|PubMed:21145359, ECO:0000269|PubMed:21192925}.
CC   -!- PTM: Ubiquitinated by FBXO3, WSB1 and SIAH1, leading to rapid
CC       proteasome-dependent degradation. The degradation mediated by FBXO3,
CC       but not ubiquitination, is prevented in the presence of PML. The
CC       degradation mediated by WSB1 and SIAH1 is reversibly reduced upon DNA
CC       damage. {ECO:0000269|PubMed:18093972, ECO:0000269|PubMed:18536714,
CC       ECO:0000269|PubMed:18809579, ECO:0000269|PubMed:33591310}.
CC   -!- PTM: Cleaved at Asp-923 and Asp-984 by CASP6 in a p53/TP53-dependent
CC       manner. The cleaved form lacks the autoinhibitory C-terminal domain
CC       (AID), resulting in a hyperactive kinase, which potentiates p53/TP53
CC       Ser-46 phosphorylation and subsequent activation of the cell death
CC       machinery. {ECO:0000269|PubMed:16601678}.
CC   -!- MISCELLANEOUS: Interesting targets for cancer therapy. HIPK2
CC       deregulation would end up in a multifactorial response leading to tumor
CC       chemoresistance by affecting p53/TP53 activity on one hand and to
CC       angiogenesis and cell proliferation by affecting HIF1A activity on the
CC       other hand. May provide important insights in the process of tumor
CC       progression, and may also serve as the crucial point in the diagnostic
CC       and therapeutical aspects of cancer. Tumor treatment may potential be
CC       improved by zinc supplementation in combination with chemotherapy to
CC       address hypoxia (PubMed:20514025). {ECO:0000305|PubMed:20514025}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. HIPK subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HIPK2ID40824ch7q34.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF208291; AAG41236.1; -; mRNA.
DR   EMBL; AF326592; AAL37371.1; -; mRNA.
DR   EMBL; AC005531; AAS00368.1; -; Genomic_DNA.
DR   EMBL; AC073184; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006021; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC141932; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF207702; AAG35710.1; -; mRNA.
DR   CCDS; CCDS75666.1; -. [Q9H2X6-3]
DR   CCDS; CCDS75667.1; -. [Q9H2X6-1]
DR   RefSeq; NP_001106710.1; NM_001113239.2. [Q9H2X6-3]
DR   RefSeq; NP_073577.3; NM_022740.4. [Q9H2X6-1]
DR   PDB; 6P5S; X-ray; 2.19 A; A=177-547.
DR   PDB; 7NCF; X-ray; 2.72 A; A=183-547.
DR   PDBsum; 6P5S; -.
DR   PDBsum; 7NCF; -.
DR   AlphaFoldDB; Q9H2X6; -.
DR   SMR; Q9H2X6; -.
DR   BioGRID; 118815; 184.
DR   CORUM; Q9H2X6; -.
DR   DIP; DIP-31716N; -.
DR   ELM; Q9H2X6; -.
DR   IntAct; Q9H2X6; 28.
DR   MINT; Q9H2X6; -.
DR   STRING; 9606.ENSP00000385571; -.
DR   BindingDB; Q9H2X6; -.
DR   ChEMBL; CHEMBL4576; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9H2X6; -.
DR   GuidetoPHARMACOLOGY; 2034; -.
DR   GlyGen; Q9H2X6; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9H2X6; -.
DR   PhosphoSitePlus; Q9H2X6; -.
DR   BioMuta; HIPK2; -.
DR   DMDM; 21431782; -.
DR   EPD; Q9H2X6; -.
DR   jPOST; Q9H2X6; -.
DR   MassIVE; Q9H2X6; -.
DR   MaxQB; Q9H2X6; -.
DR   PaxDb; Q9H2X6; -.
DR   PeptideAtlas; Q9H2X6; -.
DR   PRIDE; Q9H2X6; -.
DR   ProteomicsDB; 80628; -. [Q9H2X6-1]
DR   ProteomicsDB; 80629; -. [Q9H2X6-2]
DR   ProteomicsDB; 80630; -. [Q9H2X6-3]
DR   TopDownProteomics; Q9H2X6-2; -. [Q9H2X6-2]
DR   Antibodypedia; 9921; 365 antibodies from 32 providers.
DR   DNASU; 28996; -.
DR   Ensembl; ENST00000406875.8; ENSP00000385571.3; ENSG00000064393.16. [Q9H2X6-1]
DR   Ensembl; ENST00000428878.6; ENSP00000413724.2; ENSG00000064393.16. [Q9H2X6-3]
DR   GeneID; 28996; -.
DR   KEGG; hsa:28996; -.
DR   MANE-Select; ENST00000406875.8; ENSP00000385571.3; NM_022740.5; NP_073577.3.
DR   UCSC; uc003vvd.5; human. [Q9H2X6-1]
DR   CTD; 28996; -.
DR   DisGeNET; 28996; -.
DR   GeneCards; HIPK2; -.
DR   HGNC; HGNC:14402; HIPK2.
DR   HPA; ENSG00000064393; Tissue enriched (brain).
DR   MIM; 606868; gene.
DR   neXtProt; NX_Q9H2X6; -.
DR   OpenTargets; ENSG00000064393; -.
DR   PharmGKB; PA29291; -.
DR   VEuPathDB; HostDB:ENSG00000064393; -.
DR   eggNOG; KOG0667; Eukaryota.
DR   GeneTree; ENSGT00940000157742; -.
DR   HOGENOM; CLU_003045_1_0_1; -.
DR   InParanoid; Q9H2X6; -.
DR   OMA; THSKVYN; -.
DR   OrthoDB; 59821at2759; -.
DR   PhylomeDB; Q9H2X6; -.
DR   TreeFam; TF105417; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q9H2X6; -.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-5578768; Physiological factors.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-8939243; RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known.
DR   Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity.
DR   SignaLink; Q9H2X6; -.
DR   SIGNOR; Q9H2X6; -.
DR   BioGRID-ORCS; 28996; 10 hits in 358 CRISPR screens.
DR   ChiTaRS; HIPK2; human.
DR   GeneWiki; HIPK2; -.
DR   GenomeRNAi; 28996; -.
DR   Pharos; Q9H2X6; Tchem.
DR   PRO; PR:Q9H2X6; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9H2X6; protein.
DR   Bgee; ENSG00000064393; Expressed in medial globus pallidus and 207 other tissues.
DR   ExpressionAtlas; Q9H2X6; baseline and differential.
DR   Genevisible; Q9H2X6; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0010494; C:cytoplasmic stress granule; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0046332; F:SMAD binding; IPI:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:Ensembl.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0046790; F:virion binding; IPI:UniProtKB.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; TAS:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IDA:BHF-UCL.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0060059; P:embryonic retina morphogenesis in camera-type eye; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0001654; P:eye development; ISS:UniProtKB.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; NAS:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IBA:GO_Central.
DR   GO; GO:0061072; P:iris morphogenesis; IEA:Ensembl.
DR   GO; GO:0060235; P:lens induction in camera-type eye; IEA:Ensembl.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; IMP:FlyBase.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0030578; P:PML body organization; TAS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; ISS:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0010842; P:retina layer formation; IEA:Ensembl.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0007224; P:smoothened signaling pathway; IBA:GO_Central.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0050882; P:voluntary musculoskeletal movement; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cytoplasm;
KW   DNA damage; Host-virus interaction; Isopeptide bond; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation.
FT   CHAIN           1..1198
FT                   /note="Homeodomain-interacting protein kinase 2"
FT                   /id="PRO_0000085995"
FT   DOMAIN          199..527
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          97..230
FT                   /note="Transcriptional corepression"
FT                   /evidence="ECO:0000250"
FT   REGION          189..520
FT                   /note="Interaction with DAXX"
FT                   /evidence="ECO:0000269|PubMed:14678985"
FT   REGION          539..844
FT                   /note="Interaction with SKI and SMAD1"
FT                   /evidence="ECO:0000269|PubMed:12874272"
FT   REGION          600..800
FT                   /note="Interaction with DAZAP2"
FT                   /evidence="ECO:0000269|PubMed:33591310"
FT   REGION          752..897
FT                   /note="Interaction with POU4F1"
FT                   /evidence="ECO:0000250"
FT   REGION          774..876
FT                   /note="Interaction with CTBP1"
FT                   /evidence="ECO:0000250"
FT   REGION          787..897
FT                   /note="Interaction with HMGA1"
FT                   /evidence="ECO:0000250"
FT   REGION          792..847
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          846..941
FT                   /note="Interaction with TP53 and TP73"
FT                   /evidence="ECO:0000269|PubMed:11925430"
FT   REGION          864..885
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          873..980
FT                   /note="Required for localization to nuclear speckles"
FT                   /evidence="ECO:0000250"
FT   REGION          873..907
FT                   /note="Interaction with UBE2I"
FT                   /evidence="ECO:0000250"
FT   REGION          884..908
FT                   /note="SUMO interaction motifs (SIM); required for nuclear
FT                   localization and kinase activity"
FT   REGION          935..1049
FT                   /note="Interaction with AXIN1"
FT                   /evidence="ECO:0000250"
FT   REGION          984..1198
FT                   /note="Autoinhibitory domain (AID)"
FT   REGION          990..1056
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           802..805
FT                   /note="Nuclear localization signal 1 (NLS1)"
FT   MOTIF           832..835
FT                   /note="Nuclear localization signal 2 (NLS2)"
FT   COMPBIAS        792..833
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        324
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305"
FT   BINDING         205..213
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   BINDING         228
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   SITE            923..924
FT                   /note="Cleavage; by CASP6"
FT   SITE            984..985
FT                   /note="Cleavage; by CASP6"
FT   MOD_RES         16
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         118
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         135
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         141
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         252
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         273
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         361
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         482
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         517
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         566
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         634
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         668
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         687
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         815
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         827
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         934
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         992
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         1041
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         1155
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   MOD_RES         1188
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZR5"
FT   CROSSLNK        32
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:17018294"
FT   CROSSLNK        32
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        953
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        973
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1191
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         595..621
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_004804"
FT   VAR_SEQ         808..907
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_004805"
FT   VAR_SEQ         989..1018
FT                   /note="VNTSHHSSSYKSKSSSNVTSTSGHSSGSSS -> GNLGPGQGRNLSLESGFP
FT                   AFLLLEMLLYGS (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_004806"
FT   VAR_SEQ         1019..1198
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_004807"
FT   VARIANT         792
FT                   /note="R -> Q (in dbSNP:rs56132157)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040547"
FT   VARIANT         1027
FT                   /note="R -> Q (in dbSNP:rs35255718)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040548"
FT   MUTAGEN         228
FT                   /note="K->A: Locates in the nucleoplasm, no effect on
FT                   interaction with RANBP9, but loss of kinase activity toward
FT                   PML, RUNX1, EP300 and DAZAP2."
FT                   /evidence="ECO:0000269|PubMed:11267674,
FT                   ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11925430,
FT                   ECO:0000269|PubMed:12220523, ECO:0000269|PubMed:12874272,
FT                   ECO:0000269|PubMed:12907596, ECO:0000269|PubMed:14678985,
FT                   ECO:0000269|PubMed:18695000, ECO:0000269|PubMed:19015637,
FT                   ECO:0000269|PubMed:33591310"
FT   MUTAGEN         228
FT                   /note="K->R: Abolishes enzymatic activity, no effect on
FT                   interaction with TP53 and TP73 or on BMP-induced
FT                   transcriptional activation. Enhances BMP-induced
FT                   transcriptional activation; when associated with
FT                   359-AAF-361."
FT                   /evidence="ECO:0000269|PubMed:11267674,
FT                   ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11925430,
FT                   ECO:0000269|PubMed:12220523, ECO:0000269|PubMed:12874272,
FT                   ECO:0000269|PubMed:12907596, ECO:0000269|PubMed:14678985,
FT                   ECO:0000269|PubMed:18695000, ECO:0000269|PubMed:19015637"
FT   MUTAGEN         359..361
FT                   /note="STY->AAF: Enhances BMP-induced transcriptional
FT                   activation; when associated with R-228."
FT                   /evidence="ECO:0000269|PubMed:12874272"
FT   MUTAGEN         803
FT                   /note="K->A: Impaired nuclear localization; when associated
FT                   with A-805."
FT                   /evidence="ECO:0000269|PubMed:21145359"
FT   MUTAGEN         805
FT                   /note="K->A: Impaired nuclear localization; when associated
FT                   with A-803."
FT                   /evidence="ECO:0000269|PubMed:21145359"
FT   MUTAGEN         833
FT                   /note="R->A: Impaired nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:21145359"
FT   MUTAGEN         835
FT                   /note="K->E: Impaired nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:21145359"
FT   MUTAGEN         885..892
FT                   /note="VSVITISS->KFMHFHRM: Loss of SUMO and CBX4
FT                   interaction, and impaired nuclear and PML-nuclear bodies
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:21145359"
FT   MUTAGEN         885..888
FT                   /note="VSVI->KSAK: Loss of SUMO interaction, and impaired
FT                   nuclear and PML-nuclear bodies localization."
FT                   /evidence="ECO:0000269|PubMed:21192925"
FT   MUTAGEN         892..895
FT                   /note="SDTD->ADTA: Loss of SUMO interaction, and impaired
FT                   nuclear and PML-nuclear bodies localization."
FT                   /evidence="ECO:0000269|PubMed:21192925"
FT   MUTAGEN         893..899
FT                   /note="DTDEEEE->NFNQQQQ: Loss of SUMO and CBX4 interaction,
FT                   and impaired nuclear and PML-nuclear bodies localization."
FT                   /evidence="ECO:0000269|PubMed:21145359"
FT   CONFLICT        33
FT                   /note="I -> V (in Ref. 1; AAG41236)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        59
FT                   /note="L -> P (in Ref. 1; AAG41236)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        64
FT                   /note="T -> S (in Ref. 1; AAG41236)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        169
FT                   /note="S -> F (in Ref. 4; AAG35710)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        187
FT                   /note="V -> S (in Ref. 4; AAG35710)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        202
FT                   /note="L -> S (in Ref. 4; AAG35710)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        233
FT                   /note="H -> R (in Ref. 1; AAG41236)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        471
FT                   /note="N -> I (in Ref. 2; AAL37371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        669
FT                   /note="P -> S (in Ref. 4; AAG35710)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        711
FT                   /note="T -> N (in Ref. 4; AAG35710)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        717..719
FT                   /note="PPA -> SPT (in Ref. 4; AAG35710)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        724
FT                   /note="T -> D (in Ref. 4; AAG35710)"
FT                   /evidence="ECO:0000305"
FT   STRAND          191..193
FT                   /evidence="ECO:0007829|PDB:7NCF"
FT   STRAND          198..206
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          212..218
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          224..229
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           239..251
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           255..258
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          263..268
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          273..278
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           284..290
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   TURN            291..293
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           298..317
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           327..329
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          330..334
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   TURN            335..337
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          338..344
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           365..367
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           370..374
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           382..396
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           406..417
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           422..425
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           431..433
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          435..439
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          441..443
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   STRAND          446..448
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           451..458
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           473..476
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   TURN            477..480
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           487..507
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           512..514
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           518..522
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           525..528
FT                   /evidence="ECO:0007829|PDB:6P5S"
FT   HELIX           530..534
FT                   /evidence="ECO:0007829|PDB:6P5S"
SQ   SEQUENCE   1198 AA;  130966 MW;  6022D5710E8D2D93 CRC64;
     MAPVYEGMAS HVQVFSPHTL QSSAFCSVKK LKIEPSSNWD MTGYGSHSKV YSQSKNIPLS
     QPATTTVSTS LPVPNPSLPY EQTIVFPGST GHIVVTSASS TSVTGQVLGG PHNLMRRSTV
     SLLDTYQKCG LKRKSEEIEN TSSVQIIEEH PPMIQNNASG ATVATATTST ATSKNSGSNS
     EGDYQLVQHE VLCSMTNTYE VLEFLGRGTF GQVVKCWKRG TNEIVAIKIL KNHPSYARQG
     QIEVSILARL STESADDYNF VRAYECFQHK NHTCLVFEML EQNLYDFLKQ NKFSPLPLKY
     IRPVLQQVAT ALMKLKSLGL IHADLKPENI MLVDPSRQPY RVKVIDFGSA SHVSKAVCST
     YLQSRYYRAP EIILGLPFCE AIDMWSLGCV IAELFLGWPL YPGASEYDQI RYISQTQGLP
     AEYLLSAGTK TTRFFNRDTD SPYPLWRLKT PDDHEAETGI KSKEARKYIF NCLDDMAQVN
     MTTDLEGSDM LVEKADRREF IDLLKKMLTI DADKRITPIE TLNHPFVTMT HLLDFPHSTH
     VKSCFQNMEI CKRRVNMYDT VNQSKTPFIT HVAPSTSTNL TMTFNNQLTT VHNQAPSSTS
     ATISLANPEV SILNYPSTLY QPSAASMAAV AQRSMPLQTG TAQICARPDP FQQALIVCPP
     GFQGLQASPS KHAGYSVRME NAVPIVTQAP GAQPLQIQPG LLAQQAWPSG TQQILLPPAW
     QQLTGVATHT SVQHATVIPE TMAGTQQLAD WRNTHAHGSH YNPIMQQPAL LTGHVTLPAA
     QPLNVGVAHV MRQQPTSTTS SRKSKQHQSS VRNVSTCEVS SSQAISSPQR SKRVKENTPP
     RCAMVHSSPA CSTSVTCGWG DVASSTTRER QRQTIVIPDT PSPTVSVITI SSDTDEEEEQ
     KHAPTSTVSK QRKNVISCVT VHDSPYSDSS SNTSPYSVQQ RAGHNNANAF DTKGSLENHC
     TGNPRTIIVP PLKTQASEVL VECDSLVPVN TSHHSSSYKS KSSSNVTSTS GHSSGSSSGA
     ITYRQQRPGP HFQQQQPLNL SQAQQHITTD RTGSHRRQQA YITPTMAQAP YSFPHNSPSH
     GTVHPHLAAA AAAAHLPTQP HLYTYTAPAA LGSTGTVAHL VASQGSARHT VQHTAYPASI
     VHQVPVSMGP RVLPSPTIHP SQYPAQFAHQ TYISASPAST VYTGYPLSPA KVNQYPYI
//
